NanoCBD - Drug Programme

Despite modern antiemetics, ~30–40% of patients still experience clinically significant chemotherapy-induced nausea and/or vomiting (CINV) in routine care!

NanoCBD, similar to NanaBis in most aspects, with the exception of dronabinol. NanoCBD utilises the company’s NanoCelle, a patented delivery system, with a synthetic cannabinoid targeting chemotherapy-induced nausea and vomiting (CINV).

Work to date has been predominantly pre-clinical, with PK work shared with NanaBis due to the use of the same synthetic compound, as well as a small ethics approved, RWE program.

NanoCBD is available in foreign jurisdictions under compassionate use programmes via one of our partners.

A box and bottle of Medlab NanoCBD CBD oral spray with 17.86 mg/mL of CBD, 30 mL size, labeled for medical use..

PROGRESSION STATUS

Principle Agency: FDA

Proposed Pathway: 505(b)(2)

Initial Indication: Cancer Induced Nausea and Vomiting

Claim Expansion: Possible

Next: completion of pre-clinical

Next Trial: n/a

EA-IND : Applications closed at this time

Physician Led IND: Applications closed at this time